aprepitant + Comparator: ondansetron + Comparator: dexamethasone + Comparator: fosaprepitant dimeglumine + Comparator; Placebo (unspecified) + Comparator; Placebo (unspecified)
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-Induced Nausea and Vomiting
Conditions
Chemotherapy-Induced Nausea and Vomiting
Trial Timeline
Jan 1, 2007 โ Nov 19, 2008
NCT ID
NCT00337727About aprepitant + Comparator: ondansetron + Comparator: dexamethasone + Comparator: fosaprepitant dimeglumine + Comparator; Placebo (unspecified) + Comparator; Placebo (unspecified)
aprepitant + Comparator: ondansetron + Comparator: dexamethasone + Comparator: fosaprepitant dimeglumine + Comparator; Placebo (unspecified) + Comparator; Placebo (unspecified) is a phase 3 stage product being developed by Merck for Chemotherapy-Induced Nausea and Vomiting. The current trial status is completed. This product is registered under clinical trial identifier NCT00337727. Target conditions include Chemotherapy-Induced Nausea and Vomiting.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00337727 | Phase 3 | Completed |
Competing Products
20 competing products in Chemotherapy-Induced Nausea and Vomiting